Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance

Sponsored by

maiwald-logo-cropped.PNG
light bulb on top of ladder on yellow background

While some observers are of the view that an Enlarged Board of Appeal ruling failed to provide sufficient clarity, Eva Ehlich and Anja Fux of Maiwald say the picture concerning post-published evidence is becoming clearer

In March 2023, the EPO’s Enlarged Board of Appeal (EBA) issued a much-awaited decision in case G 2/21 on the topic of ‘plausibility’. This catchword is often applied in the context of the required quality of disclosure and evidence in an application as filed for a contested purported technical effect to be further supported by post-published evidence.

The question may arise in the context of inventive step (Article 56 of the European Patent Convention, or EPC) or sufficiency of disclosure (Article 83 EPC), if the effect is expressly claimed.

When the written decision of G 2/21 was finally published, there was some disillusionment regarding the concreteness of the provided guidelines because the decision remains rather abstract.

It is therefore not surprising that the guidance given by the technical boards of appeal applying the criteria given in G 2/21 was equally much awaited. While the case law will continue to develop, there are several decisions that shed light on the interpretation. In particular, the decision T 0116/18 (Board of Appeal 3.3.02) on the case underlying G 2/21 is now available, having been published online on November 27 2023.

T 0116/18: standard under inventive step – the purported effect is not claimed

This decision relates only to inventive step (the purported technical effect is not specified in the claim) and gives very detailed guidance for the application of the criteria for the allowance of post-published evidence in this context.

The Board of Appeal applies a twofold test derived from Headnote II of G 2/21; namely, whether the purported effect would be:

  • “Encompassed by the technical teaching”; and

  • “Embodied by the same originally disclosed invention”.

It concludes that neither a verbatim statement nor an experimental proof of the effect is required.

Referring to national decisions on the Apixaban case, the Board of Appeal expressly rejected the standard of plausibility applied by the Court of Appeal in England and Wales and the requirement of a positive verbal statement of the effect in the application as filed by the Dutch Court of Appeal. Rather, in the context of the first bullet point above, it suffices that the purported technical effect together with the claimed subject matter is conceptually comprised by the broadest technical teaching of the application as filed.

And in the context of the second bullet point above, a question to be answered is whether the effect is irreconcilable with the common general knowledge, taking into account the application as filed.

Based on this level of evidence, the Board of Appeal concluded in this case that the purported effect is, in fact:

  • Encompassed by the technical teaching; and

  • Embodied by the same originally disclosed invention.

Without going into all the details of the underlying case, the authors conclude that the reasoning provides quite a lot of flexibility for applicants or patentees to use post-published evidence, as long as the effect is within the general concept disclosed and does not prompt disbelief in the sense of what could be considered as not ‘ab initio implausible’, or now summarised as ‘irreconcilable with the common general knowledge’.

The EPO practice leans towards the very old German approach: G 2/21 cites a still-valid decision by the German Federal Court of Justice from 1972, X ZB 2/71 – Imidazoline, which generously allows post-published evidence to substantiate inventive step.

Most other decisions citing G 2/21 rendered in the context of inventive step (the effect is not claimed), meanwhile, seem equally generous in this respect, although not all apply the twofold test. See T 0873/21 (3.3.07), T 0728/21 (3.3.07), T 1445/21 (3.3.07), T 1989/19 (3.3.02; in German), T 0681/21 (3.3.06; regarding an auxiliary request), T 0885/21 (3.3.07), and T 1329/21 (3.3.07). Only two decisions, T 0258/21 (3.3.07) and T 0887/21 (3.3.04), and T 0681/21 regarding the main request, did not accept the purported technical effect in accordance with G 2/21.

G 2/21: different standard under sufficiency – the purported effect is claimed

In the authors’ opinion, an important further, and now rather clear, learning from G 2/21 is the higher standard to be applied on the credibility of an effect when it relates to sufficiency of disclosure.

While the concrete questions to be answered by the EBA arising from the underlying case were in the context of inventive step, the standard for such an effect under sufficiency of disclosure (the purported technical effect is specified in the claim) was also considered. The guidelines for sufficiency are now only in the body of the reasoning and not in the order providing the binding answers to the questions. It can nevertheless be assumed that those guidelines will be applied by the technical boards of appeal.

The EBA summarises in paragraph 77 of G 2/21 that the scope of reliance on post-published evidence for sufficiency is much narrower. The EBA states, albeit only in the context of therapeutic effects, that a lack of proof, or at least credible disclosure, in the application as filed cannot be remedied with post-published evidence. This appears to be the old standard of ab initio plausibility.

In any event, looking at the guidelines for inventive step and how these are now applied and the guidelines for sufficiency of disclosure side by side, the level of evidence required at the filing date clearly differs. While an effect must be credible for sufficiency of disclosure, the standard is lower under inventive step in that the effect must only be conceptually comprised by the broadest technical teaching and not be irreconcilable with the common general knowledge (like the former ab initio implausible standard).

Maiwald graphic.png
more from across site and ros bottom lb

More from across our site

Michelle Lue-Reid has joined the IP business as its chief transformation officer and will look to implement major change initiatives across member firms
Chad Landmon, who joins in Washington DC, hopes to expand the firm’s Hatch-Waxman practice
The FRAND rate is only 5 cents higher than the per-device rate determined at first instance in 2023
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Nearly four months after joining Crowell & Moring, Edward Taelman reflects on starting afresh, new clients, and firm culture
Firms discuss the ebb and flow of life sciences IP work and explain how they help professionals pivot between specialities
Mercedes-Benz, Dolby Laboratories, and Panasonic discuss the merits and drawbacks of the USPTO's terminal disclaimer proposal
In-house counsel believe Chinese domestic firms are becoming as sophisticated as international firms, but they may not shift their portfolios just yet
The Court of Appeals for the Federal Circuit is looking to renew a ban that has prevented Judge Pauline Newman from hearing cases
The list of the top representative firms at the UPC may yield few surprises but their success did not come free
Gift this article